SCHEMBL4022380

SCHEMBL4022380

CNC(=O)CN1C[C@H](C(=O)c2cccc(OC)c2)C(c2cccc(F)c2C)[C@@H](C(=O)c2cccc(OC)c2)C1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM2B Q8NHM5 5/20 0.43
ALDH1A1 P00352 2/20 0.41
TSHR P16473 1/20 0.40
KMT2A Q03164 3/20 0.40
HTT P42858 1/20 0.40
LMNA P02545 1/20 0.40
GRIN2B Q13224 1/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
RAB9A P51151 1/20 0.39
MEN1 O00255 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.38
THRB P10828 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
DRD2 P14416 1/20 0.38
DRD4 P21917 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4022383 1.00 KDM2B (0.43) KDM2BALDH1A1TSHRKMT2AHTT
SCHEMBL4027951 0.88 KDM2B (0.43) KDM2BALDH1A1KMT2AHTTLMNA
SCHEMBL4027956 0.88 KDM2B (0.43) KDM2BALDH1A1KMT2AHTTLMNA
SCHEMBL4019453 0.88 DRD4 (0.37) KDM2BALDH1A1KMT2ALMNAGRIN2B
SCHEMBL4019455 0.88 DRD4 (0.37) KDM2BALDH1A1KMT2ALMNAGRIN2B
SCHEMBL4021398 0.86 KDM2B (0.45) KDM2BALDH1A1KMT2AHTTLMNA
SCHEMBL4024597 0.86 KDM2B (0.45) KDM2BALDH1A1KMT2AHTTLMNA
SCHEMBL4751954 0.85 DRD4 (0.44) KDM2BKMT2AHTTDRD2DRD4
SCHEMBL4025349 0.85 DRD4 (0.43) KDM2BKMT2AHTTDRD2DRD4
SCHEMBL13721307 0.84 KDM2B (0.43) KDM2BALDH1A1KMT2AHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 KDM2B 3090/4885ALDH1A1 258/4885TSHR 4351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.